Boundless Bio, Inc. (BOLD): Cash & Equivalents
$17.87M
As of 2025-12-31
$20.21M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.87M | -32.8% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $26.59M | +12.2% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $23.71M | n/a | 2025-03-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $17.87M | -32.8% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $30.23M | +2.4% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $137.53M | +148.7% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $19.96M | -18.8% |
| Veradermics, Inc (MANE) | 2025-12-31 | $21.77M | -59.0% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $17.81M | +206.5% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $12.67M | -66.7% |
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $14.04M | -70.3% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $13.15M | -50.0% |
Compare BOLD, PGEN, XLO, ACRS side by side · Screen every company in Pharmaceutical Preparations ↗